Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

EBV-associated Malignancies Clinical Trial

Official title: An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases

Status Completed

Clinical Trial Summary

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• EBV-associated Malignancies
• EBV-induced Lymphomas
• Lymphoma
• Lymphoproliferative Disorders
• Neoplasms
• Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
• Viremia

• NCT number: NCT00002663
• Study type: Interventional
• Source: Atara Biotherapeutics
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: March 1995
• Completion date: July 2019